Left and right ventricular global longitudinal strain assessment together with biomarker evaluation may have a predictive and prognostic role in patients qualified for hematopoietic stem cell transplantation due to hematopoietic and lymphoid malignancies - a pilot study description.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardio-oncology Pub Date : 2024-02-17 DOI:10.1186/s40959-024-00210-8

Bartosz Puła, Jarosław Kępski, Irena Misiewicz-Krzemińska, Sebastian Szmit

{"title":"Left and right ventricular global longitudinal strain assessment together with biomarker evaluation may have a predictive and prognostic role in patients qualified for hematopoietic stem cell transplantation due to hematopoietic and lymphoid malignancies - a pilot study description.","authors":"Bartosz Puła, Jarosław Kępski, Irena Misiewicz-Krzemińska, Sebastian Szmit","doi":"10.1186/s40959-024-00210-8","DOIUrl":null,"url":null,"abstract":"<p><p>The hematopoietic stem cell transplantation (HSCT) procedure is considered a cardiovascular burden. This is due to the potentially cardiotoxic cytostatic agents used before and the risks associated with peri-transplant procedures. We designed a pilot study to determine the clinical utility of the new ST2 marker; furthermore, we routinely assessed cardiac parameters in HSCT recipients. Based on previous cardio-oncology experience in lung and prostate cancer, we can confirm the prognostic and predictive value of classic cardiac biomarkers and modern echocardiography parameters such as global longitudinal strain of the left and right ventricle. After conducting this pilot study we can create a predictive and prognostic model for patients undergoing HSCT. This will greatly enrich our clinical practice, especially in treating older people.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10873966/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-024-00210-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The hematopoietic stem cell transplantation (HSCT) procedure is considered a cardiovascular burden. This is due to the potentially cardiotoxic cytostatic agents used before and the risks associated with peri-transplant procedures. We designed a pilot study to determine the clinical utility of the new ST2 marker; furthermore, we routinely assessed cardiac parameters in HSCT recipients. Based on previous cardio-oncology experience in lung and prostate cancer, we can confirm the prognostic and predictive value of classic cardiac biomarkers and modern echocardiography parameters such as global longitudinal strain of the left and right ventricle. After conducting this pilot study we can create a predictive and prognostic model for patients undergoing HSCT. This will greatly enrich our clinical practice, especially in treating older people.

查看原文本刊更多论文

左心室和右心室整体纵向应变评估与生物标志物评估可对因造血和淋巴恶性肿瘤而符合造血干细胞移植条件的患者起到预测和预后作用--一项试点研究的描述。

造血干细胞移植（HSCT）过程被认为是心血管负担。这是因为移植前使用的细胞抑制剂可能会对心脏造成毒性，而且移植围手术过程也存在风险。我们设计了一项试点研究，以确定新 ST2 标记的临床实用性；此外，我们还对造血干细胞移植受者的心脏参数进行了常规评估。根据以往在肺癌和前列腺癌方面的心脏肿瘤学经验，我们可以确认经典心脏生物标记物和现代超声心动图参数（如左室和右室的整体纵向应变）的预后和预测价值。开展这项试验研究后，我们可以为接受造血干细胞移植的患者建立一个预测和预后模型。这将极大地丰富我们的临床实践，尤其是在治疗老年人方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊